Prevention of Vein Graft Failure
预防静脉移植失败
基本信息
- 批准号:8974847
- 负责人:
- 金额:$ 0.75万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2003
- 资助国家:美国
- 起止时间:2003-04-01 至 2016-04-30
- 项目状态:已结题
- 来源:
- 关键词:AcuteAnti-Inflammatory AgentsAnti-inflammatoryApoptosisAutologousBiological ProcessBlood CirculationBlood VesselsBypassCell physiologyCessation of lifeClinicCoronary Artery BypassDevelopmentEndotheliumEventExtracellular Matrix ProteinsGoalsHarvestHealthHumanHyperplasiaInjuryLeadLimb structureMechanicsModelingMorbidity - disease rateMuscle functionMyocardial InfarctionOperative Surgical ProceduresOrganOrgan PreservationOrgan TransplantationPatientsPeripheralPost-Translational Protein ProcessingPreparationPreventionProcessProductionPropertyReactive Oxygen SpeciesRecurrenceSalineSaphenous VeinSignal TransductionSkinSmooth MuscleSmooth Muscle MyocytesStretchingSurgeonTechniquesTherapeuticTherapeutic InterventionTimeTranslatingTransplantationVein graftVeinscostgraft failureimplantationmigrationmortalityoperationpreventresponseresponse to injurysenescence
项目摘要
DESCRIPTION (provided by applicant): Human greater saphenous vein (HSV) is the most commonly used conduit for coronary artery bypass grafting (CABG) and the most effective conduit for infrainguinal peripheral vascular bypass grafting (PVBG). However, the rate of vein graft failure remains high (45% at 1-11/2 years) and there is no current therapeutic approach that has yet been shown to reduce vein graft failure in humans. HSV is harvested from the extremity and "prepared" prior to implantation. During this process, surgeons typically manually stretch and distend the HSV, store the conduit in heparinized saline, and mark the vein to prevent twisting or kinking on implantation. These maneuvers cause significant injury to the cellular components of the conduit which leads to intimal hyperplasia and vein graft failure. HSV represents an autologous organ that is transplanted into the arterial circulation. Despite the many advances in organ preservation, the current techniques used to prepare and preserve HSV do not adequately protect the transplanted vein. The hypothesis of this proposal is that injury to the cellular components of HSV during preparation lead to intimal hyperplasia and vein graft failure. The corollary to this hypothesis is that minimizing injury at the time of surgical preparation will impact subsequent vein graft patency. This proposal will develop elegantly simple approaches to prevent injury during graft preparation as well as promote our understanding of the processes that lead to vein graft intimal hyperplasia. The potential impact of this proposal is to develop optimal vein preparation techniques that can be readily translated into the clinic thus reducing the morbidity, mortality, and costs associated with vein graft failur.
描述(由申请人提供):人大隐静脉(HSV)是冠状动脉旁路移植术(CABG)最常用的管道,也是腹股沟下外周血管旁路移植术(PVBG)最有效的管道。然而,静脉移植失败的发生率仍然很高(1-11/2年时为45%),目前还没有显示出减少人类静脉移植失败的治疗方法。HSV是从四肢采集的,并在植入前进行“准备”。在此过程中,外科医生通常手动拉伸和扩张HSV,将导管储存在肝素化盐水中,并标记静脉以防止植入时扭曲或扭结。这些操作会对导管的细胞成分造成严重损伤,导致内膜增生和静脉移植失败。HSV代表移植到动脉循环中的自体器官。尽管在器官保存方面取得了许多进展,但目前用于制备和保存HSV的技术不能充分保护移植静脉。该建议的假设是,在制备过程中对HSV的细胞成分的损伤导致内膜增生和静脉移植失败。该假设的推论是,手术准备时尽量减少损伤将影响随后的静脉移植物通畅性。这项建议将发展优雅简单的方法,以防止在移植准备过程中的损伤,以及促进我们的理解的过程中,导致静脉移植内膜增生。该提案的潜在影响是开发最佳的静脉准备技术,这些技术可以很容易地转化为临床,从而降低与静脉移植失败相关的发病率、死亡率和成本。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Colleen M Brophy其他文献
Colleen M Brophy的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Colleen M Brophy', 18)}}的其他基金
Cell permeant peptidomimetics to prevent delayed vasospasm and neurological deficits after subarachnoid hemorrhage
细胞渗透性肽模拟物可预防蛛网膜下腔出血后迟发性血管痉挛和神经功能缺损
- 批准号:
10384341 - 财政年份:2022
- 资助金额:
$ 0.75万 - 项目类别:
相似海外基金
Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals
开发作为抗炎剂和砷解毒剂的小分子抑制剂
- 批准号:
10727507 - 财政年份:2023
- 资助金额:
$ 0.75万 - 项目类别:
Discovery of New Anti-Inflammatory Agents to Treat COPD
发现治疗慢性阻塞性肺病的新型抗炎药
- 批准号:
9194162 - 财政年份:2016
- 资助金额:
$ 0.75万 - 项目类别:
Synthesis of anti-inflammatory agents and their structure-activity relationships studies
抗炎药的合成及其构效关系研究
- 批准号:
496858-2016 - 财政年份:2016
- 资助金额:
$ 0.75万 - 项目类别:
University Undergraduate Student Research Awards
NAAA Inhibitors as Anti-inflammatory Agents, Phase II
NAAA 抑制剂作为抗炎剂,II 期
- 批准号:
9201955 - 财政年份:2015
- 资助金额:
$ 0.75万 - 项目类别:
Novel flavonoids as anti-inflammatory agents in alcoholism
新型黄酮类化合物作为酒精中毒的抗炎剂
- 批准号:
8251289 - 财政年份:2014
- 资助金额:
$ 0.75万 - 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
- 批准号:
8302750 - 财政年份:2012
- 资助金额:
$ 0.75万 - 项目类别:
Design and in vivo delivery of novel anti-inflammatory agents
新型抗炎剂的设计和体内递送
- 批准号:
267940 - 财政年份:2012
- 资助金额:
$ 0.75万 - 项目类别:
Operating Grants
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
- 批准号:
8403458 - 财政年份:2012
- 资助金额:
$ 0.75万 - 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
- 批准号:
8472443 - 财政年份:2012
- 资助金额:
$ 0.75万 - 项目类别:
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
- 批准号:
8549297 - 财政年份:2012
- 资助金额:
$ 0.75万 - 项目类别: